Use of tetrahydrocannabivarin (THCV) and/or cannabidiol (CBD) in the treatment of epilepsy

Use of the phyto-cannabinoids tetrahydrocannabivarin (THCV) and/or cannabidiol (CBD) in the treatment of epilepsy and more particularly generalized (tonic and/or clonic) and/or partial seizures. The daily dose of THCV is preferably at least 1.5 mg and more preferably at least 15 mg. The daily dose of CBD is preferably at least 400 mg and more preferably 400-800 mg. The embodiments relate to the use of pure CBD or to the use of THCV, as a pure compound or as a plant extract in which significant amounts of any THC naturally present has been selectively removed.